Cargando…

Downregulation of miR-217 correlates with resistance of ph(+) leukemia cells to ABL tyrosine kinase inhibitors

This study found that long-term exposure of chronic myelogenous leukemia (CML) K562 cells to BCR/ABL thyrosine kinase inhibitors (TKI) caused drug-resistance in association with an increase in levels of DNA methyltransferases (DNMT) and a decrease in levels of microRNA miR-217. These observations ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishioka, Chie, Ikezoe, Takayuki, Yang, Jing, Nobumoto, Atsuya, Tsuda, Masayuki, Yokoyama, Akihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317938/ https://www.ncbi.nlm.nih.gov/pubmed/24350829 http://dx.doi.org/10.1111/cas.12339

Ejemplares similares

Blockade of CD82 by a monoclonal antibody potentiates anti-leukemia effects of AraC in vivo
por: Nishioka, Chie, et al.
Publicado: (2015)

Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells
por: Nishioka, Chie, et al.
Publicado: (2015)

MicroRNA‐9 plays a role in interleukin‐10‐mediated expression of E‐cadherin in acute myelogenous leukemia cells
por: Nishioka, Chie, et al.
Publicado: (2017)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin
por: Pan, Bin, et al.
Publicado: (2017)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy
por: Riva, G, et al.
Publicado: (2011)

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
por: Boer, Judith M., et al.
Publicado: (2016)

Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase
por: Aleem, Saadat U., et al.
Publicado: (2015)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
por: He, Fang, et al.
Publicado: (2021)

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Terasawa, Teruhiko, et al.
Publicado: (2011)

Tyrosine kinase c-Abl regulates the survival of plasma cells
por: Li, Yan-Feng, et al.
Publicado: (2017)

Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry
por: Min, Saehong, et al.
Publicado: (2017)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies
por: Motaln, Helena, et al.
Publicado: (2023)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2017)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
por: Aghel, Nazanin, et al.
Publicado: (2017)

Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
por: He, Fang, et al.
Publicado: (2021)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
por: Amarante-Mendes, Gustavo P., et al.
Publicado: (2022)

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
por: Eiring, Anna M., et al.
Publicado: (2015)

BCL6 enables Ph(+) acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition
por: Duy, Cihangir, et al.
Publicado: (2011)

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M, et al.
Publicado: (2006)

Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
por: Luttman, Jillian Hattaway, et al.
Publicado: (2021)

Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation
por: Daniels, Hannah G., et al.
Publicado: (2022)

An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia
por: Zimmermannova, O, et al.
Publicado: (2017)

Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia
por: Singh, Neetu, et al.
Publicado: (2018)

Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
por: Vinhas, Raquel, et al.
Publicado: (2017)

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016)

Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias
por: Smith, Stephanie M., et al.
Publicado: (2021)

Src- and Abl-family kinases activate spleen tyrosine kinase to maximize phagocytosis and Leishmania infection
por: Ullah, Imran, et al.
Publicado: (2023)

Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
por: Kim, Yeojae, et al.
Publicado: (2022)

A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
por: Limsuwanachot, Nittaya, et al.
Publicado: (2023)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lqlcmq1o52snnd36ch76icdq56